Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Personalis to Present at Upcoming Investor Conferences


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the following upcoming investor conferences.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's NeXTtm Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).


These press releases may also interest you

at 02:05
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the...

at 02:05
Masimo today announced the results of a study published in Pneumonia in which independent researchers in New Delhi, India, investigated the accuracy of Masimo RRp® on pediatric patients with the Rad-Gtm Pulse Oximeter by comparing it to...

at 02:00
With one in five people suffering from the annual attack of itchy red eyes and constant sneezing, and with the pollen count set for HIGH, on-demand laundry app, Laundrapp, shares its top five tips ? from bedding to intimacy ? for protecting against...

at 01:35
Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ? ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders,...

at 01:35
Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central...

at 01:00
Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of...



News published on 19 november 2019 at 16:10 and distributed by: